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Abstract
Background: Fremanezumab (TEV-48125) is a fully humanized anti-calcitonin gene-related peptide (CGRP)
monoclonal antibody (mAb) that has shown positive results in the prevention of episodic migraine and chronic
migraine. Previous preclinical studies have revealed CGRP antagonistic effects on intracranial arteries (ICA). The aim
of the study was to evaluate the in vitro antagonistic effects of fremanezumab on human arteries.
Methods: Arteries were removed in conjunction with neurosurgery (cerebral, CA, and middle meningeal artery,
MMA, n = 7) or reconstructive abdominal surgery (abdominal artery, AA, n = 6). Ring segments of the vessels were
mounted in a sensitive myograph, the functional responses of vasoactive intestinal peptide (VIP), substance P and
CGRP in increasing concentrations (10− 10–10− 7 M) were studied using pre-contraction with 30 mM potassium
chloride (KCl). The concentrations of fremanezumab or isotype control antibody (66.7 nM, 0.33 μM, 0.67 μM) were
given 30 min prior to CGRP administration.
Results: All included arteries responded with a strong stable contraction to the application of 30 mM KCl. During
this pre-contraction, CGRP caused a concentration-dependent relaxation which differed slightly in maximum effect
(Imax) between the types of arteries (ICA = 100%; AA 80%). Fremanezumab (66.7 nM) showed a shift in the IC50 value
of CGRP, but no significant change in Imax. At higher doses there was also a reduction of Imax. For AA, the Imax
decreased from 71% at 66.7 nM, to 4.5% with 0.33 μM of fremanezumab. Isotype control antibody did not modify
the responses. There was no effect on concentration-dependent relaxation with VIP with 66.7 nM of fremanezumab
or isotype control.
Conclusion: CGRP relaxes pre-contracted human arteries by 80–100%, but with different IC50; the potency range was
ICA < AA. The antagonistic effect and potency of fremanezumab was similar, suggesting that there are vasodilatory
CGRP receptors present in all studied arteries and that the antibody may have effect in all studied vessels.
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Background
Calcitonin gene-related peptide alpha (αCGRP) is a
37-amino acid neuropeptide belonging to the calcitonin
family of peptides. It is abundant in the circulation.
CGRP is widely distributed throughout the central, per-
ipheral and enteric nervous systems [1] and has strong
vasodilatory properties, especially in the peripheral
microvasculature [2] and in the cerebral circulation [3].
CGRP increases cAMP in human, feline and rodent vas-
cular smooth muscle cells (VSMC) [4, 5] and is also ac-
tive in endothelium-denuded cerebral arteries as well as
in meningeal arteries [6]. The vasomotor actions of
αCGRP are implied in a variety of both physiological
and pathological processes, including migraine and other
primary headaches as well as cerebral vasospasm after
subarachnoid hemorrhage [7].
Monoclonal antibodies against CGRP or its receptor
are currently being evaluated for the prevention of epi-
sodic migraine and chronic migraine; all available
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clinical trials have shown positive results [8–11]. How-
ever, as with all new medications, care has to be taken in
order to evaluate possible risks of adverse events such as
stroke, hypertension, and myocardial infarction; one way
is to study human vessels [12].
Fremanezumab is a fully humanized monoclonal anti-
body that potently and selectively binds to both isoforms
(α and β) of CGRP and thereby prevents CGRP from
binding to the CGRP receptor. Therapeutic monoclonal
antibodies to CGRP such as fremanezumab have been de-
veloped because of the very high target specificity, long
pharmacokinetic half-lives, and markedly low potential for
hepatic toxicity [8, 13] and in phase 2 and 3 clinical
studies, fremanezumab was shown to be an effective and
safe migraine treatment [8, 14, 15]. Recently, Edvinsson et
al. explained the long time it has taken from finding CGRP
to the new medications like gepants (small molecules) and
the monoclonal antibodies against CGRP or against the
CGRP receptor. Human cranial arteries have been a
method to understand how CGRP blocking agents modify
the vascular responses to CGRP [16].
The present study was designed to evaluate the in
vitro vascular effects of fremanezumab (TEV-48125,
formerly LBR-101) on isolated human cerebral, middle
meningeal and abdominal arteries.
Methods
Human meningeal (n = 4) and cerebral cortical (n = 3)
arteries were removed during neurosurgical operations
for intracranial tumors (4 male and 3 female). Human
subcutaneous arteries (n = 6, female) were obtained from
reconstructive abdominal surgery. The study was
approved by the human ethics committee of Lund
(LU818–01) and written informed consent was given by
all vessel donors.
After removal, the vessels were immediately immersed in
4 °C cold cell culture medium (DMEM containing essential
nutrients and antibiotics) (Gipco, ThermoFisher Scientific,
Waltham, MA USA 02451). The vessels were carefully dis-
sected and transferred to cold sodium buffer solution (NaCl
119 mM, NaHCO3 15 mM, KCl 4.6 mM, CaCl2 1.5 mM,
NaH2PO4 1.2 mM, MgCl 1.2 mM and glucose 5.6 mM),
pH 7.4, and stored in refrigerator at 4°Covernight.
Substances
CGRP, vasoactive intestinal peptide (VIP) and substance
P were purchased from Bio-Techne (Abingdon, UK).
Common substances for buffer preparation were pur-
chased from Sigma-Aldrich (St Louis, MO, USA).
Myography
In order to evaluate the dilatory response to CGRP
(10− 10 – 10− 7 M), VIP (10− 10 – 10− 7 M) and substance P
(10− 9 – 10− 8 M), in human arteries a Mulvany-Halpern
Wire Myograph (Danish Myo Technology A/S, Aarhus,
Denmark) was used as has been previously described [17].
Vessel segments (1–2 mm) were placed in a tissue bath in
5 ml sodium buffer solution (NaCl 119 mM, NaHCO3
15 mM, KCl 4.6 mM, CaCl2 1.5 mM, NaH2PO4 1.2 mM,
MgCl 1.2 mM and glucose 5.6 mM). The solution was
kept at 37 °C and was continuously aerated with air with
5% CO2 to maintain pH at 7.4. Depending on the thick-
ness of the artery, the vessels were mounted either on pins
200 μm thick or on two 40 μm wires, which were inserted
into the vessel lumen. The pins/wires were connected to a
force transducer and a micrometer screw. Normalization
was performed by successive manipulation of the microm-
eter screw until the vessel segments were stretched to 90%
of the normal internal circumference, which is the diam-
eter they would have if relaxed under a transmural pres-
sure of 100 mmHg [18]. After 30 min of recovery, viability
of the vessel segments were determined by replacing the
sodium buffer with a 63.5 mM potassium buffer [19]
(NaCl 119 mM, NaHCO3 15 mM, KCl 63.5 mM, CaCl2,
1.5 mM, NaH2PO4, 1.2 mM, MgCl 1.2 mM, and glucose
5.6 mM); the contractile response was measured as 100%
contraction by the respective vessel segment. After observ-
ing the contractile response to high potassium twice, tissue
baths were washed in the above mentioned sodium buffer.
Endothelial viability was then tested by pre-contract the ves-
sels with 30 mM potassium-buffer, and after stabilization,
successive concentrations of substance P 10− 8 – 10− 7 M
were added, which, if the endothelium was viable, would in-
duce a transient vasodilation. After this step, the potassium
buffer was again washed out and replaced with the above
mentioned sodium buffer. The vessels were pre-treated with
either fremanezumab antibody or the isotype control anti-
body (KLH) for 20 min. To test the dilatory response to
CGRP, the vessels were pre-contracted with 30 mM
potassium-buffer for 10 min followed by dose response of
antibody. The concentrations of the antibodies were 10, 50,
and 100 μg/ml (66.7 nM, 0.33 μM, 0.67 μM, respectively) in
the vessel baths, which was in the same range as used in the
chronic migraine clinical study [8, 20]. Contraction forces
were recorded through a PowerLab unit (ADInstruments,
Chalgrove, UK).
Statistics
Relaxations are expressed as percentage of the pre-ten-
sion induced by 30 mM potassium buffer. All
concentration-response curves were analyzed by iterative
non-linear regression analysis using GraphPad Prism
7.02 (GraphPad Corp, San Diego, CA, USA). Imax is the
maximal response developed to the agonist. IC50 is the
concentration that produced half maximum dilatation.
Results are given as mean +/− standard error of the
mean (SEM) and n is the number of patients used in the
respective group. Statistical analyses were performed
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with non-parametric Mann-Whitney (two groups) and
Kruskal-Wallis followed by Dunn’s multiple comparison
test (three or four groups) non-parametric tests. Results
were considered as significant if p < 0.05.
Results
Arteries from human subcutaneous and intracranial arteries
were found to have functional endothelium as tested in ar-
tery segments pre-contracted by performing the experiments
in a buffer containing 30 mM potassium. The addition of
substance P resulted in a concentration-dependent relaxation
of the artery segments. For subcutaneous arteries, 10− 9 M
substance P dilated pre-contracted arteries by 49.8%± 22.7
and at 10− 8 M by 66.2% ± 21.4 (mean ± SEM). The re-
laxant responses were at the same concentrations of
substance P in meningeal and cortical arteries 17.3%
± 16.2 and 26.1% ± 20.6, respectively.
Following washout with standard buffer solution, the
vessels relaxed to baseline and after equilibrium, again
the 30 mM potassium buffer was added. In these arter-
ies, CGRP resulted in relaxation by as much as 80–100%
of the pre-contraction by increasing concentrations of
CGRP (10− 10 – 10− 7 M) (Figs 1 and 2). We observed no
difference in the responses to the endothelial function
check at these two time-points.
At the lowest concentration of fremanezumab in the
tissue bath (10 mg/L, 66.7 nM), the results showed that
the Imax was the same as in the control, but the IC50 was
increased (a shift to the right) for all three types of arter-
ies. In addition, no effect was seen by fremanezumab per
se (neither dilatation nor contraction).
At the higher dose of fremanezumab, a delayed dilatation
of abdominal arteries was observed with concentrations >
1 nM CGRP. With 100 nM fremanezumab and control, the
Imax was reduced and the IC50 increased (Table 1, Fig. 1).
After pre-treatment with 50 or 100 μg/mL (0.33 or 0.67 μM)
fremanezumab or isotype control, there was no dilatation
with any concentration of CGRP (tested up to 0.1 μM, data
not shown). Due to the similar effect in this assay with the
isotype control, the effect of these higher antibody concentra-
tions on dilatation cannot be attributed to the sequestration
of CGRP.
Cerebral and middle meningeal arteries responded
in a similar manner with a significantly delayed dila-
tation in the presence of 10 μg/mL (66.7 nM) frema-
nezumab antibody (Fig. 2, Table 1). There was a
shift in IC50 towards the right indicating change in
Imax. Result also showed no relaxation by fremanezu-
mab or the isotype antibody control per se in ICA
(data not shown). Addition of 50 μg/mL (0.33 μM)
fremanezumab or its isotype control inhibited the
CGRP-induced dilatation completely. Therefore, no
higher concentration was tested.
In abdominal and intracranial arteries, the study
tested whether the antibodies had any effect on vaso-
dilatation induced by VIP (Figs. 3 and 4). Neither fre-
manezumab nor the isotype control antibody had any
effect on the VIP-induced dilatation of the cerebral
arteries at the doses of 66.7 nM (Figs. 3 and 4) or
0.33 μM (data not shown).
Fig. 1 Human abdominal subcutaneous arteries were pre-contracted
with 30 mM potassium buffer. The curves show dilatation in response to
increasing concentrations of αCGRP 10− 11 to 10− 7 M in the presence of
66.7 nM of the monoclonal antibody against CGRP (fremanezumab) or an
isotype control (KLH). The data show mean± SEM, n= 2–4 for each
concentration. CGRP:calcitonin gene-related peptide; K:potassium; TEV:Teva
Fig. 2 Human intracranial arteries were pre-contracted with 30 mM
potassium buffer. The curves show dilatation in response to increasing
concentrations of αCGRP 10− 11 to 10− 7 M in the presence of 66.7 nM of
the monoclonal antibody against CGRP (fremanezumab) or an isotype
control (KLH). The data show mean± SEM, n=2–4 for each concentration.
CGRP:calcitonin gene-related peptide; K:potassium; TEV:Teva
Table 1 Relaxant responses to CGRP in the presence or
absence of 66.7 nM fremanezumab or its isotype control
Abdominal arteries Intracranial arteries
Imax (%) IC50 (nM) Imax (%) IC50 (nM)
CGRP control curve 82 ± 4 2.1 ± 0.1 78 ± 22 1.1 ± 0.5
+ fremanezumab 66.7 nM 71 ± 3 182 ± 1.0 49 ± 11 752 ± 9
+ isotype control 66.7 nM 71 ± 9 3.2 ± 0.2 55 ± 12 2.9 ± 0.4
CGRP: calcitonin gene-related peptide, IC50: concentration of CGRP in nM that
produced half the maximum dilatation, Imax: maximum dilatation induced by
CGRP when the pre-contraction by 30 mM potassium buffer is set to 100%
Values are mean ± SEM
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Discussion
The present study shows that the monoclonal antibody
against CGRP, fremanezumab, effectively and selectively
blocks the vasomotor responses to CGRP in prepara-
tions of human intracranial and peripheral arteries.
Migraine is a highly prevalent disorder characterized
by attacks of headache and associated symptoms such as
nausea, photophobia, and phonophobia. Most individ-
uals with migraine have episodic migraine, but some
have a more severe form known as chronic migraine.
The burden of episodic or chronic migraine on the per-
son with migraine, their family, and society at large is
substantial [21].
CGRP, a neuropeptide with two isoforms (αCGRP and
βCGRP), is believed to be crucial to the pathophysiology
of migraine and is therefore an attractive target in the
development of migraine preventive strategies. CGRP
seems to be involved in peripheral events in migraine
(vasodilation, inflammation, and protein extravasation)
and is abundantly distributed in the trigeminal ganglion
and in the brain [21]. Inhibition of the CGRP pathway
has demonstrated efficacy in the acute and preventive
treatment of migraine [16, 22, 23]. The first suggestion
to use a CGRP receptor antagonist for migraine therapy
was made in 1985 [24], however, it has taken more than
three decades to reach the clinic [16]. The subsequent
testing of such a receptor antagonist or an antagonist
antibody on cerebral [25] and middle meningeal arteries
[26]. The likely site of action residing outside the
blood-brain barrier (BBB) putatively on meningeal ves-
sels or trigeminal ganglion [27, 28].
This study was designed to study in some detail the antag-
onistic effects of fremanezumab, a fully humanized monoclo-
nal antibody that targets CGRP, on the CGRP-mediated
dilatation of human cerebral, meningeal, and abdominal ar-
teries at clinically relevant concentrations. One clear effect
was the lack of effect per se of the antibody, thus indicating
no tonus by CGRP in these circulations [7]. We observed
that the CGRP-induced relaxations in pre-contracted seg-
ments behave rather similarly in all three vascular regions
and was in concert with previous work (with same IC50 and
Imax) [29]. At the lowest concentration of fremanezumab
(66.7 nM), CGRP-induced relaxation showed a parallel shift
to the right with no change in maximum dilatation and no
effect by the isotype control antibody solution. At higher
concentrations of fremanezumab, the arterial response to
CGRP was markedly reduced or even absent as a sign of
strong antagonism. However, the isotype control also had
equal effect on arterial relaxation but only at the highest con-
centration as well, suggesting that some of these data at the
higher concentrations may be artefact and is not a contribu-
tion of CGRP sequestration. This is commonly seen with
high antibody concentrations using in vitro assays and is one
of the reasons that we use an isotype control antibody.
It is unknown if fremanezumab may have an effect on
several of the receptors belonging to the calcitonin family
receptors; future studies may be designed to evaluate also
the effects of fremanezumab on the vascular responses to
the other calcitonin family member peptides (adrenome-
dullin, intermedin, amylin and calcitonin). These peptides
also activate CGRP receptors so essentially, we are only
looking at one component of the receptor action in this in
vitro system, which may not represent the normal milieu
of peptides occurring in patients.
Previous studies using gepants [29] revealed a com-
petitive antagonistic response with a shift of the
concentration-response curve to the right, allowing the
calculation of the dissociation constant. The behavior of
fremanezumab thus differs from gepants, because the
antibody acts as a “sink” in removing CGRP from the
myography test system, a likely manner of interaction in pa-
tients. The specificity at the 66.7 nM concentration of fre-
manezumab was verified by unaltered relaxant responses to
Fig. 3 Human abdominal subcutaneous arteries were pre-contracted
with 30 mM potassium buffer. The curves show dilatation in response
to increasing concentrations of VIP 10− 11 to 10− 7 M in the presence of
66.7 nM of the monoclonal antibody against CGRP (fremanezumab) or
an isotype control (KLH). The data show mean ± SEM, n = 2–4 for each
concentration. K:potassium; TEV:Teva; VIP:vasoactive intestinal peptide
Fig. 4 Human intracranial arteries were pre-contracted with 30 mM
potassium buffer. The curves show dilatation in response to increasing
concentrations of VIP 10− 11 to 10− 7 M in the presence of 66.7 nM of the
monoclonal antibody against CGRP (fremanezumab) or an isotype control
(KLH). The data show mean ± SEM, n= 2–4 for each concentration.
K:potassium; TEV:Teva; VIP:vasoactive intestinal peptide
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VIP (a known peptide mediator of VIPR1 and VIPR2 recep-
tors, but has no effect on CGRP receptors) and the con-
tractile effects of 30 mM potassium buffer.
The antibody fremanezumab appears to have a direct
functional effect on CGRP-induced relaxation in the
tested human arteries with no change in maximum dila-
tation at the 66, 7 nM concentration. The fremanezu-
mab/CGRP dissociation constant cannot be determined
in this experiment due to its extremely high affinity for
CGRP, and because the off rate is substantially longer
than the time frame of each experiment.
Conclusion
The results of this study showed that the humanized
monoclonal antibody fremanezumab can compete with
CGRP to a similar extent in different human arteries.
The long half-life of the interaction is relevant in a
“chronic” situation or in prophylaxis because a patient
will be exposed to the antibody for a longer period of
time and will therefore, at some point, be at steady state
with respect to the equilibrium constant of the anti-
body/antigen interaction. The antagonistic effect and po-
tency of fremanezumab was similar in the different
arteries studied, suggesting that there are vasodilatory
CGRP receptors present in all studied arteries and that
the antibody may have effect in all studied vessels.
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